研究单位：[1]Peking Union Medical College Hospital[2]Peking University Third Hospital[3]Beijing Jishuitan Hospital[4]Beijing Chao Yang Hospital[5]Xuanwu Hospital, Beijing[6]Peking University First Hospital[7]Jilin Provincial Tumor Hospital[8]Second Hospital of Shanxi Medical University[9]The First Affiliated Hospital of Shanxi Medical University[10]Tianjin Medical University General Hospital[11]The First Affiliated Hospital of Anhui Medical University
The purpose of this study is to evaluate the real-world efficacy and safety of ixazomib, lenalidomide, or ixazomib in combination with lenalidomide as maintenance therapy in patients with newly diagnosed multiple myeloma in China.
